Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Prometheus Biosciences logo

About Prometheus Biosciences Stock (NASDAQ:RXDX)

Advanced Chart

Key Stats

Today's Range
$199.92
$199.92
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
N/A
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Prometheus Biosciences (NASDAQ: RXDX)
See More Headlines

RXDX Stock Analysis - Frequently Asked Questions

Prometheus Biosciences, Inc. (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. Prometheus Biosciences's revenue was down 71.8% on a year-over-year basis.

Prometheus Biosciences subsidiaries include Prometheus Laboratories Inc..

Prometheus Biosciences (RXDX) raised $126 million in an initial public offering on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA).

Company Calendar

Last Earnings
5/09/2023
Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.75 million
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Price / Cash Flow
N/A
Book Value
$16.12 per share
Price / Book
12.40

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:RXDX) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners